Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RTX 117

Next Previous
Drug Profile

RTX 117

Alternative Names: RTX-117

Latest Information Update: 09 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ReviR Therapeutics
  • Class RNA; Small molecules
  • Mechanism of Action Eukaryotic initiation factor 2b modulators; RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Charcot-Marie-Tooth disease
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Charcot-Marie-Tooth disease

Most Recent Events

  • 13 Oct 2025 Preclinical trials in Charcot-Marie-Tooth disease in USA (PO)
  • 13 Oct 2025 RTX 117 receives Orphan Drug status for Charcot-Marie-Tooth disease in USA
  • 13 Oct 2025 ReviR Therapeutics plans to initiate a phase I trial for Charcot-Marie-Tooth disease (Healthy volunteers) (PO) in early 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top